| Dr Mary Margaret Mullen, MD | |
|
4921 Parkview Pl, Div Obgyn Gynecologic Oncology, Ste 13c, Saint Louis, MO 63110-1032 | |
| (314) 362-3181 | |
| (314) 362-2893 |
| Full Name | Dr Mary Margaret Mullen |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 10 Years |
| Location | 4921 Parkview Pl, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437563897 | NPI | - | NPPES |
| 200058975 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 2018005682 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Barnes Jewish Hospital | Saint louis, MO | Hospital |
| Missouri Baptist Medical Center | Town and country, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Washington University | 9830008770 | 2506 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Public health experts from across Canada will meet in Toronto March 11 and 12 to review and discuss planning outreach to populations vulnerable to HIV infection and sexually transmitted and blood borne infections (STBBI). The meeting will be hosted by Winnipeg's National Collaborating Centre for Infectious Diseases.
The first comprehensive assessment of the acrylamide content of smokeless tobacco products (STPs) has shown that exposure to acrylamide through STP use is much smaller than -approximately 1% of - exposure from the diet or from cigarette smoking.
Seeing oneself as overweight or obese may be an important, independent predictor of suicidal thoughts, especially in young girls, reports a new study in the Journal of Adolescent Health.
› Verified 2 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Public health experts from across Canada will meet in Toronto March 11 and 12 to review and discuss planning outreach to populations vulnerable to HIV infection and sexually transmitted and blood borne infections (STBBI). The meeting will be hosted by Winnipeg's National Collaborating Centre for Infectious Diseases.
The first comprehensive assessment of the acrylamide content of smokeless tobacco products (STPs) has shown that exposure to acrylamide through STP use is much smaller than -approximately 1% of - exposure from the diet or from cigarette smoking.
Seeing oneself as overweight or obese may be an important, independent predictor of suicidal thoughts, especially in young girls, reports a new study in the Journal of Adolescent Health.
› Verified 2 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972771657 PECOS PAC ID: 7416865845 Enrollment ID: O20031218000354 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Public health experts from across Canada will meet in Toronto March 11 and 12 to review and discuss planning outreach to populations vulnerable to HIV infection and sexually transmitted and blood borne infections (STBBI). The meeting will be hosted by Winnipeg's National Collaborating Centre for Infectious Diseases.
The first comprehensive assessment of the acrylamide content of smokeless tobacco products (STPs) has shown that exposure to acrylamide through STP use is much smaller than -approximately 1% of - exposure from the diet or from cigarette smoking.
Seeing oneself as overweight or obese may be an important, independent predictor of suicidal thoughts, especially in young girls, reports a new study in the Journal of Adolescent Health.
› Verified 2 days ago
| Entity Name | Washington University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760422265 PECOS PAC ID: 9830008770 Enrollment ID: O20040812001332 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Public health experts from across Canada will meet in Toronto March 11 and 12 to review and discuss planning outreach to populations vulnerable to HIV infection and sexually transmitted and blood borne infections (STBBI). The meeting will be hosted by Winnipeg's National Collaborating Centre for Infectious Diseases.
The first comprehensive assessment of the acrylamide content of smokeless tobacco products (STPs) has shown that exposure to acrylamide through STP use is much smaller than -approximately 1% of - exposure from the diet or from cigarette smoking.
Seeing oneself as overweight or obese may be an important, independent predictor of suicidal thoughts, especially in young girls, reports a new study in the Journal of Adolescent Health.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary Margaret Mullen, MD Po Box 60352, Saint Louis, MO 63160-0352 Ph: (314) 362-3181 | Dr Mary Margaret Mullen, MD 4921 Parkview Pl, Div Obgyn Gynecologic Oncology, Ste 13c, Saint Louis, MO 63110-1032 Ph: (314) 362-3181 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Public health experts from across Canada will meet in Toronto March 11 and 12 to review and discuss planning outreach to populations vulnerable to HIV infection and sexually transmitted and blood borne infections (STBBI). The meeting will be hosted by Winnipeg's National Collaborating Centre for Infectious Diseases.
The first comprehensive assessment of the acrylamide content of smokeless tobacco products (STPs) has shown that exposure to acrylamide through STP use is much smaller than -approximately 1% of - exposure from the diet or from cigarette smoking.
Seeing oneself as overweight or obese may be an important, independent predictor of suicidal thoughts, especially in young girls, reports a new study in the Journal of Adolescent Health.
› Verified 2 days ago
Dr. Patricia Tereese Jimenez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4444 Forest Park Ave, Div Ob Reproductive Endocrinology, Ste 3100, Saint Louis, MO 63108 Phone: 314-286-2400 Fax: 314-286-2455 | |
Anna Rabinov, ANNA RABINOV Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-747-3000 | |
Shannon Michelle Grabosch, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1031 Bellevue Ave Ste 400, Saint Louis, MO 63117 Phone: 314-781-4772 Fax: 314-645-8771 | |
Dr. Kathryn Botney, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 621 S New Ballas Rd, Suite 4005, Saint Louis, MO 63141 Phone: 314-567-5016 Fax: 314-567-1846 | |
Dr. Ann Marie S Rockamann, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3023 N Ballas Rd Ste 600d, Saint Louis, MO 63131 Phone: 314-996-4880 | |
Dr. Haifaa T. Younis, M.D Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2315 Dougherty Ferry Rd, Suite 109b, Saint Louis, MO 63122 Phone: 314-965-5553 Fax: 314-590-5972 | |
Dr. Renee M Stein, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10777 Sunset Office Dr, Suite 200, Saint Louis, MO 63127 Phone: 314-842-4802 Fax: 314-849-8721 |